Helix BioPharma Corp. (HBP.TO)

0.1900 +0.0050 (+2.70%) At close: 03:55PM EDT

Helix BioPharma Corp.

9120 Leslie Street
Suite 205
Richmond Hill, ON L4B 3J9
Canada
905 841 2300
https://www.helixbiopharma.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 10

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Artur Gabor	Chief Exec. Officer	60k	N/A	1960
Mr. Hatem Kawar M.B.A., MBA, P.Eng, P.Eng.	Chief Financial Officer	N/A	N/A	1959
Ms. Namrata Malhotra	Corp. Sec.	N/A	N/A	N/A

Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CAD.

Description

Helix BioPharma Corp. operates as an immune-oncology company in Canada. It is developing L-DOS47 for the treatment of non-small cell lung cancer; and V-DOS47 that targets the vascular epithelial growth factor receptor 2. Helix BioPharma Corp. has collaboration agreements with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors; and with ProMab Biotechnologies, Inc. to develop novel antibody and chimeric antigen receptor T-cell therapy to treat multiple myeloma, as well as a license agreements with Xisle Pharma Ventures Trust and National Research of Council Canada. The company is headquartered in Richmond Hill, Canada.

Corporate Governance

Helix BioPharma Corp.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.